Lifastuzumab vedotin (
INN; development code DNIB0600A) is an experimental monoclonal
antibody-drug conjugate designed for the treatment of cancer.
Statement On A Nonproprietary Name Adopted By The USAN Council - Lifastuzumab Vedotin
'' American Medical Association''.
This drug was developed by Genentech
Genentech, Inc., is an American biotechnology corporation headquartered in South San Francisco, California. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within R ...
/ Roche.
References
{{monoclonals for tumors
Experimental cancer drugs
Monoclonal antibodies for tumors
Antibody-drug conjugates